The pathway leading to the intracellular association of antigenic peptides with major histocompatibility complex (MHC) class I molecules involves several distinct steps, some of which are increasingly better understood (reviewed in references 10, 12, 20, 26, and 27). Cytoplasmic antigen, as found following viral infections or certain bacterial infections (e.g., those caused by Listeria and Shigella spp.), is degraded in an enzymedependent process reportedly involving a proteasome complex. Peptide fragments are selectively transported to the lumen of the endoplasmic reticulum (ER), where peptides satisfying correct binding motifs interact with nascent MHC class I molecules, which are then transported to the cell surface. Although many aspects of the endogenous pathway seem widely accepted, a concise model of peptide selection as it occurs within this pathway remains elusive.
The pathway leading to the intracellular association of antigenic peptides with major histocompatibility complex (MHC) class I molecules involves several distinct steps, some of which are increasingly better understood (reviewed in references 10, 12, 20, 26, and 27) . Cytoplasmic antigen, as found following viral infections or certain bacterial infections (e.g., those caused by Listeria and Shigella spp.), is degraded in an enzymedependent process reportedly involving a proteasome complex. Peptide fragments are selectively transported to the lumen of the endoplasmic reticulum (ER), where peptides satisfying correct binding motifs interact with nascent MHC class I molecules, which are then transported to the cell surface. Although many aspects of the endogenous pathway seem widely accepted, a concise model of peptide selection as it occurs within this pathway remains elusive.
We have used the induction of MHC class I-restricted CD8 ϩ cytotoxic T lymphocytes (CTLs) to a defined epitope within the listeriolysin O (LLO) molecule to investigate features of antigen processing and epitope selection within the endogenous antigen presentation pathway. LLO is a hemolysin secreted by Listeria monocytogenes and is a virulence factor required for escape of the bacterial parasite from the phagocytic vacuole to the cytoplasm of the host cell, where bacterial replication occurs (4, 24) . In BALB/c (H2 d ) mice at least five distinct nanomer peptides which satisfy the H2-K d binding motif exist within the LLO molecule; however, the LLO amino acid 91 to 99 (aa91-99) peptide provides the only epitope for the induction of peptide-specific CTLs (7, 23, 28) . In an attempt to alter the postulated endogenous selection of LLOderived peptides for subsequent MHC class I association, we have introduced a point mutation within the hly (LLO gene) sequence which results in a tyrosine-to-phenylalanine substitution (underlined residues) at amino acid 92 (GYKDGNEYI to GFKDGNEYI), thus altering the anchor residue of the resulting aa91-92F-99 peptide. We hypothesized that the conservative substitution of Y to F would not alter the biology of LLO as a virulence factor but might alter the MHC class I-presented CTL target epitope display, perhaps allowing other peptides of LLO to be recognized following endogenous processing.
We have found that the F-92 mutation does not alter the kinetics of LLO production, the LLO activity, or the general immunogenicity of the "92F" L. monocytogenes mutant which carries it. BALB/c mice immunized with the 92F L. monocytogenes mutant are resistant to lethal challenge with wild-type L. monocytogenes. However, CTLs obtained from BALB/c mice immunized with the 92F mutant do not possess anti-LLO specific cytolytic activity when tested against target cells pulsed with LLO aa91-99, LLO aa91-92F-99, or the other peptides derived from LLO which bind H2-K d . Thus, the conservative amino acid substitution of Y to F does not alter the biology of the LLO molecule as a virulence factor but apparently eliminates the induction of all H2-K d -restricted cytotoxic responses directed against this key virulence determinant. Additionally, the lack of a CTL response specific for K d -presented LLO ) (ATCC TIB 64). The LLO aa91-99 peptide (single-letter code, GYKDGNEYI) was synthesized at the Veterans Affairs Biochemistry Core Facility; the LLO aa91-92F-99 peptide (GFK-DGNEYI) was purchased from Research Genetics; and LLO aa69-77 (DYNKNNVLV), LLO aa192-200 (KYAQAYPNV), LLO aa413-421 (AYTD GKINI), and LLO aa479-487 (VYAKECTGL) were purchased from SynPep (Dublin, Calif.). All peptides were purified by high-pressure liquid chromatography to a purity of greater than 95%.
Bone marrow macrophage cultures. Bone marrow was obtained from femurs of BALB/c or C57BL/6 mice and cultured in 24-well plates at 7.5 ϫ 10 4 cells per well in 1 ml of DMEM containing 10 g of gentamicin (Sigma) per ml, 20% FCS, and 30% L-cell supernatant (as a source of colony-stimulating factor 1) at 37ЊC and 7.5% CO 2 in air. After 6 days, the bone marrow macrophages (BM-MAC) were washed twice with 37ЊC DMEM and incubated in 1 ml of DMEM with 10% FCS (no antibiotics) for an additional 18 h. We routinely recovered 1 ϫ 10 5 to 2 ϫ 10 5 BM-MAC per well. Construction of the LLO Y-92-to-F-92 mutant strain. Mutagenesis by overlap extension PCR (15) was used to construct L. monocytogenes DP-L2528, in which codon 92 of hly was changed from ATG to AAG (coding strand), resulting in substitution of phenylalanine for tyrosine 92 in LLO. Briefly, a fragment spanning bp Ϫ186 to 877 of hly (19) and containing a T-to-A substitution at bp 326 was generated from L. monocytogenes 10403S genomic DNA by using flanking primers 5Ј-CCGGATCCGGCCCCCTCCTTTGATT-3Ј and 5Ј-GGCTGCAGT AGTAACAGCTTTGCCG-3Ј (which contains 5Ј BamHI and PstI sites, respectively) and internal primers 5Ј-TCCATCTTTGAAACCTTTTC-3Ј and 5Ј-GAA AAGGTTTCAAAGATGGA-3Ј. The site of mutagenesis is underlined in the internal primers. The final PCR-mutagenized fragment was cloned into the BamHI and PstI sites of the temperature-sensitive suicide vector pKSV7. Replacement of the wild-type chromosomal sequence with the mutated sequence cloned into pKSV7 was accomplished by allelic exchange. The chromosomal mutation was confirmed by amplifying from DP-L2528 or wild-type genomic DNA a fragment spanning bp Ϫ144 to 776 of hly by using primers 5Ј-TTTATG TGGATCCATTAACATTTGT-3Ј and 5Ј-GGGGATCCTTCACTGATTGCGC C-3Ј. Fragments were cloned into plasmid pAM401 (29) and sequenced by the dideoxy method using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, Ohio).
Cell culture. Spleen cells from mice immunized 6 days previously with L. monocytogenes were stimulated in culture with 1.0 g of concanavalin A (ConA; Sigma) per ml in RPMI 1640 (Gibco) containing 100 U of penicillin (Sigma) per ml, 100 g of streptomycin (Sigma) per ml, 5% FCS, and 5 ϫ 10 Ϫ5 M 2-mercaptoethanol (Sigma). A total of 10 8 cells in 50 ml were cultured in a 75-cm 2 flask for 72 h at 37ЊC in humidified air with 7.5% CO 2 . In several experiments, BALB/c or C57BL/6-derived Listeria-immune spleen cells obtained 14 days following immunization were stimulated in culture with either viable wild-type L. monocytogenes at a multiplicity of infection (MOI) of 0.1 to 1 or a viable LLO-producing B. subtilis transformant. The LLO-producing B. subtilis transformant was added following IPTG (Sigma)-induced hly expression, at an MOI of 1 to 5. Tetracycline at 12.5 g/ml and gentamicin at 40 g/ml were added 2 h following initiation of the cultures. Following culture, the recovered cells were either used in assays of CTL activity or adoptively transferred to naive recipients at 2 ϫ 10 7 to 4 ϫ 10 7 per recipient in a 0.2-ml volume via the tail vein. CFU reduction assay. Target cells were deposited, at 2 ϫ 10 5 per well, in 24-well tissue culture plates in 1.0 ml of antibiotic-free DMEM supplemented with nonessential amino acids and 5% FCS 18 h before the assay (2, 8) . The target cell monolayers were infected with L. monocytogenes at MOIs of 2 to 5 for J774 cells and 10 to 20 for BM-MAC. After 60 min, the monolayers were washed three times with sterile phosphate-buffered saline (PBS; 37ЊC) and covered with 0.5 ml of DMEM containing 5% FCS and 40 g of gentamicin sulfate per ml. Effector cells (typically at an effector/target [E/T] ratio of 20:1) were added in 0.5 ml of DMEM with 5% FCS 3 to 4 h after initiation of the infection. The assays were terminated 4 h later, and the number of intracellular bacteria remaining in each well was determined. Specifically, the medium was aspirated and replaced with 1 ml of distilled water. Five minutes later, dilutions were plated onto brain heart infusion agar plates, which were incubated for 24 h at 37ЊC, and the number of CFU was determined. Data are presented as percent CFU reduction as determined by the following formula: [1 Ϫ (CFU in target monolayers incubated with effector cells)/(CFU in target monolayers incubated without effector cells)] ϫ 100.
Chromium release assay with peptide-pulsed target cells. Four million P815 cells were incubated with 150 to 200 Ci of 51 Cr (specific activity, 447.52 MCi/ mg; New England Nuclear) for 1 h and washed three times with DMEM. The 51 Cr-labeled cells were then incubated at 10 5 /ml for 30 min with peptides and transferred (without washing) in 0.1-ml aliquots of 10 4 cells to wells of roundbottom microtiter plates (Nunc). Effector cells (typically at an E/T ratio of 50:1) were then added in 0.1 ml to appropriate wells. After 4 h of incubation, the 96-well plates were centrifuged and 0.15 ml of supernatant was removed from each well for analysis. The results are presented as percent 51 Cr release as determined by the following formula: 100 ϫ [(experimental release Ϫ background release)/(maximum release Ϫ background release)].
Determination of log 10 protection. Twenty-one days following immunization (no detectable bacteria from the primary immunization are present at this time), groups of four to five mice each were challenged with approximately a 10-LD 50 dose of viable L. monocytogenes 10403 in 0.2 ml injected via the tail vein. The spleens were removed 48 h later and homogenized individually in 4.5 ml of PBS with 1% Proteose Peptone by using a tissue homogenizer (Tekmar). The homogenates were serially diluted and plated onto brain heart infusion agar. Log 10 protection was determined by subtracting the mean of the log 10 CFU per spleen values of the test group from the mean of the log 10 CFU per spleen values of the normal control group.
Assay for hemolysin production. Ten to 20 ml of brain heart infusion broth was inoculated with 0.2 ml from an overnight suspension culture of L. monocytogenes and incubated in a shaking 37ЊC water bath for 8 to 10 h. Approximately 2 ml of the sample was centrifuged at 10,000 ϫ g for 10 min, and the supernatant was filter sterilized. Serial twofold dilutions of the supernatant were prepared in a 5 mM dithiothreitol citrate-phosphate buffer, pH 5.5 (Sigma), in a volume of 0.5 to 1.0 ml. After a 30-min incubation at 37ЊC, a 1/10 volume of a 10% sheep erythrocyte suspension (Prepared Media Labs, Portland, Oreg.) was added to each sample for an additional 30-min incubation at 37ЊC. The samples were centrifuged at 300 ϫ g for 5 to 10 min, and the A 541 of the supernatant was determined. The level of LLO production was determined by linear regression analysis, and 1 U of LLO activity is defined as the reciprocal of the dilution which gives 50% of the maximal hemoglobin release.
LD 50 determination. Three-to fivefold serial dilutions of overnight suspension cultures of L. monocytogenes strains were prepared in saline and injected intravenously into the tails of BALB/c mice in a 0.2-ml volume. Two to three mice were injected per dilution sample. Mice were monitored twice daily, and mice in a moribund state were euthanized. The LD 50 dose was determined by noting the doses which allowed survival compared with the doses which were lethal. Therefore, LD 50 data are presented as ranges rather than absolute values.
Intracellular growth curve. J774 target cells were deposited, at 2 ϫ 10 5 per well, in 24-well tissue culture plates in 1.0 ml of antibiotic-free DMEM supplemented with nonessential amino acids and 5% FCS 18 h before the assay. J774 monolayers were infected with L. monocytogenes at an MOI of 2 to 5. After 60 min, the monolayers were washed three times with sterile PBS (37ЊC) and covered with 1.0 ml of DMEM containing 5% FCS and 40 g of gentamicin sulfate per ml. At 1, 2, 4, or 8 h after initiation of the infection, the number of intracellular bacteria in each well was determined. For this analysis, the medium was aspirated and replaced with 1 ml of distilled water. Five minutes later, dilutions were plated onto brain heart infusion agar plates, which were incubated for 24 h at 37ЊC, and the number of CFU was determined.
RESULTS
Kinetics of LLO production and intracytoplasmic growth of the 92F L. monocytogenes mutant. We introduced a point mutation within hly of L. monocytogenes which results in a tyrosine (Y)-to-phenylalanine (F) substitution (underlined) at amino acid position 92 within the LLO protein (GYKDGNEYI to GFKDGNEYI). DNA sequence analysis of the mutated hly showed that the codon for tyrosine (TAC) at amino acid position 92 within hly was substituted for the codon for phenylalanine (TTC) (Fig. 1) . In order to demonstrate that the conservative Y-to-F substitution at amino acid 92 within the LLO molecule did not alter the virulence phenotype of the 92F L. monocytogenes mutant, we assessed the LD 50 of the 92F L. monocytogenes mutant, the levels of LLO secreted in vitro by the 92F mutant, and the intracellular growth of the 92F VOL. 64, 1996 ELIMINATION OF LLO-SPECIFIC CTLs 3729 mutant within monolayers of the J774 macrophage-like cell line.
In BALB/c mice, the LD 50 of wild-type L. monocytogenes is approximately 1 ϫ 10 4 to 3 ϫ 10 4 CFU. BALB/c mice were injected with the 92F mutant, and we found the LD 50 of the 92F mutant to be approximately 2 ϫ 10 4 to 4 ϫ 10 4 CFU, which is unaltered compared with that of wild-type L. monocytogenes.
LLO is a secreted protein, and the hemolytic activity of LLO can be detected in supernatants of bacterial suspension cultures. Log-phase cultures were established (the 92F mutant and wild-type L. monocytogenes possess equivalent growth rates in suspension culture), and we found that wild-type L. monocytogenes and the 92F mutant secrete similar levels of LLO activity into the culture supernatants, with both strains secreting hemolysin at levels in the range of 35 to 55 U/ml.
In order to determine if the Y-to-F substitution at amino acid 92 in LLO influences intracytoplasmic growth of L. monocytogenes (24, 25) , J774 cells were infected with the 92F mutant and its growth in J774 cells was compared with that of wildtype L. monocytogenes. We found the intracellular growth curves for the 92F mutant and wild-type L. monocytogenes within J774 monolayers to be indistinguishable (data not shown). These results demonstrate that the F-92 substitution within the LLO molecule does not alter LLO activity, LLOdependent phagosome escape or intracellular growth, or virulence as assessed by LD 50 .
Antilisterial immunity is induced following subclinical infection with the 92F mutant. The data presented above show that the virulence phenotype of the 92F mutant is essentially identical to that of wild-type L. monocytogenes. To determine if the 92F mutation alters the kinetics and in vivo persistence of the 92F mutant following subclinical infection, we injected mice with wild-type L. monocytogenes or the 92F mutant and, 24, 48, and 72 h later, determined the numbers of splenic CFU. The data presented in Fig. 2A show that the bacterial load from mice immunized with the 92F mutant was equivalent at all time points to the number of splenic CFU from wild-type L. monocytogenes-immunized mice. Six days following immunization, the infection was essentially resolved for all strains. We next determined the consequences of the F-92 mutation for induction and expression of antilisterial immunity. Figure  2B shows that animals immunized with the 92F mutant were resistant to subsequent challenge with either the 92F mutant or wild-type L. monocytogenes. Additionally, animals immunized with wild-type L. monocytogenes showed equivalent levels of antilisterial protection following challenge with either wildtype L. monocytogenes or the 92F mutant. These results show that the F-92 mutation does not alter the induction or expression of antilisterial immunity.
The target specificity of antilisterial cytotoxic cells from 92F mutant-immunized mice does not include the LLO aa91-99 peptide. The 92F L. monocytogenes mutant was constructed in order to investigate endogenous processing of the LLO molecule and the in situ selection of H2-K d -associated LLO-derived determinants for subsequent induction of antilisterial CTLs. Figure 3A shows results of an experiment in which the cytolytic activity of antilisterial CTLs from animals immunized with either wild-type L. monocytogenes or the 92F mutant against P815 targets pulsed with either LLO aa91-99 or LLO aa91-92F-99 peptides was determined. Although antilisterial CTLs from wild type-immunized mice lysed LLO aa91-99 and LLO aa91-92F-99 peptide-pulsed targets to equivalent extents, antilisterial CTLs from 92F mutant-immunized mice did not lyse the peptide-pulsed P815 targets. However, Fig. 3B shows that antilisterial CTLs from mice immunized with the 92F mutant   FIG. 1 . DNA sequencing verifies the Y-to-F substitution in DP-L2528. DNA fragments containing the mutant and wild-type alleles of hly were amplified from strains DP-L2528 and 10403S, respectively, and sequenced as described in Materials and Methods. The sequence of the coding strand is shown. The sequences of the DP-L2528 (92F strain) and wild-type LLO aa91-99 epitopes and the corresponding amino acids are indicated. 3B . CTLs from wild-type L. monocytogenes-immune mice display specificity for the Listeria-infected targets similar to that seen with CTLs from mice previously immunized with the 92F mutant. These results demonstrate that CTLs from mice immunized with the 92F mutant lyse Listeria-infected targets with specificity for non-LLO-derived determinants; however, CTLs with specificity for the LLO aa91-99 or LLO aa91-92F-99 determinant were not apparent.
Target cells infected with the 92F mutant are not lysed by LLO-specific CTLs. The data presented above suggest that the LLO aa91-92F-99 peptide-MHC class I complex as might be expected to be found following infection with the 92F mutant does not stimulate CTLs. To determine if target cells infected with the 92F mutant are lysed by LLO-specific CTLs, spleen cells from wild-type L. monocytogenes-immunized BALB/c mice were stimulated in culture with an LLO-producing B. subtilis transformant (9) . We have previously shown that stimulation of antilisterial CTLs with these culture conditions results in the expansion of only LLO-specific CTL numbers (9) . Figure Fig. 6A show that when the peptide-pulsed target cells were added to CTLs immediately following the washing step, the levels of cytolysis for LLO aa91-99-and aa91-92F-99-pulsed target cells were equivalent. This situation was also observed when the targets were added to the antilisterial CTLs 30 min following the washing step. However, when the peptide-pulsed target cells were added to the antilisterial CTLs 90 min following the washing step to remove unbound peptide, the cytolysis of the LLO aa91-92F-99-pulsed target cells was decreased by approximately 90%. In contrast, under identical conditions, no decrease in cytolysis of LLO aa91-99-pulsed cells was observed. These results suggest that the LLO aa91-92F-99-K d complex is relatively unstable and rapidly dissociates from the cell surface and, conversely, that the LLO aa91-99-K d complex is relatively stable as a target for antilisterial CTLs. In order to show that following the apparent dissociation of the LLO aa91-92F-99-K d complex, P815 cells could still become targets of antilisterial CTLs, the LLO aa91-99 peptide was added back 90 min following the initial washing step (i.e., after a period in which the susceptibility to lysis is apparently lost), and following an additional 45-min incubation with peptide, the P815 target cells were added to the antilisterial specific CTLs at an E/T ratio of 50:1. The data presented in Fig. 6B show that in a manner similar to that observed for the results in panel A, the cytolysis of LLO aa91-92F-99-pulsed target cells was markedly decreased 90 min following washing and removal of unbound peptide. However, when the LLO aa91-99 peptide was added back to these target cells, susceptibility to cytolysis was restored to control levels. These data show that a stable LLO aa91-99-K d complex can be restored on targets previously pulsed with the LLO aa91-92F-99 peptide and that the LLO aa91-99-K d complex renders these target cells susceptible to lysis mediated by antilisterial CTLs.
92F mutant LLO provides a target for H2 b -restricted CTLs. To determine if the Y-92-to-F substitution disrupts normal endogenous processing of the LLO molecule such that no MHC class I presentation of any LLO-derived determinants occurs, C57BL/6 mice (H2 b ) were immunized with the 92F L. monocytogenes mutant and immune spleen cells were stimulated in culture with the LLO ϩ B. subtilis transformant, a procedure used previously to expand only LLO reactive CTLs in culture (9) . We used as targets Listeria-infected BM-MAC in a standard CFU reduction assay (7) . The targets were infected with Listeria strains which allowed discrimination of LLO and non-LLO determinant-specific CTL responses. Ϫ9 M LLO aa91-99 was added to the P815 cells, and the targets cells were incubated for an additional 45 min and then added to antilisterial CTLs at an E/T ratio of 50:1. For each time point, the assay was terminated 4 h following addition of the effector cells and specific 51 Cr release was determined as described in Materials and Methods. The data are from one representative experiment of four performed.
LLO
Ϫ L. monocytogenes mutant. This serves as an additional control for nonspecific lysis of infected targets. If the levels of CFU reduction observed in these experiments were due simply to nonspecific events, we would expect that targets infected with the LLO Ϫ mutant would also show similar levels of CFU reduction, and this was not observed. Figure 7 also shows results obtained by using spleen cells from C57BL/6 mice immunized with wild-type L. monocytogenes following stimulation in culture with the LLO ϩ B. subtilis transformant, and the results for percent CFU reduction of Listeria-infected BM-MAC targets were similar in pattern and magnitude to the results observed with antilisterial CTLs from C57BL/6 mice immunized with the 92F mutant. These results show that in H2 b mice, 92F mutant LLO is processed to yield an LLOderived MHC class I-presented epitope which is a CTL target and suggests that the presence of phenylalanine at amino acid 92 does not result in a general lack of endogenous processing of the LLO molecule and subsequent MHC class I presentation of LLO-derived determinants.
DISCUSSION
In an attempt to alter the immunodominance of LLO aa91-99 as a target for antilisterial CTLs in mice immunized with L. monocytogenes, we introduced a point mutation within hly (the gene for LLO) which results in a tyrosine-to-phenylalanine substitution at amino acid position 92 of LLO. This change (underlined) alters the anchor residue at position 2 within the nanomer LLO aa91-99 epitope (GYKDGNEYI to GFKDGNEYI). This conservative amino acid substitution does not alter the virulence parameters that were measured, i.e., LLO secretion and activity, LD 50 , and intracellular growth in J774 monolayers. However, as the data presented in this report show, following immunization with the 92F L. monocytogenes mutant, no CTL responses to LLO-derived peptides were evident. Although the LLO aa91-92F-99 peptide binds H2-K d and LLO aa91-92F-99-pulsed cells are targets of antilisterial CTLs from wild-type L. monocytogenes-immunized donors (Fig. 3) , CTLs obtained from 92F mutant-immune mice did not lyse targets pulsed with LLO aa91-99 or LLO aa91-92F-99 ( Fig. 3 and 5) .
The absence of an LLO response in mice immunized with the 92F mutant indicates that any association of 92F mutantderived LLO peptides with MHC class I molecules which may occur following endogenous processing of the F-92 form of LLO does not reach the surface of infected cells at the magnitude or level of stability required to stimulate a cytotoxic cell response. This conclusion is supported by the data presented in Fig. 6 which show that as a CTL target the LLO aa91-92F-99-MHC class I complex is rapidly lost on peptide-pulsed target cells. This is in contrast to the relative stability of the LLO aa91-99-K d complex on peptide-pulsed target cells. In addition, the findings as presented in Fig. 4 indicate that cells infected with the 92F mutant are not targets of LLO-specific cytotoxic cells, an observation which suggests that the aa91-92F-99 peptide does not reach the surface of the infected cell in an H2-K d -associated complex in even the limited density required for recognition by CTLs (17) . However, H2-K b mice which have a peptide binding motif not influenced by an F-92 substitution possess CTLs reactive with LLO-derived epitopes that are apparent following immunization with the 92F mutant (Fig. 7) . This observation is consistent with the premise that the 92F mutant LLO molecule is readily processed and enters the MHC class I pathway for transport to the cell surface. Since P815 cells become targets of LLO-specific target cells following exogenous labeling with either the aa91-99 or the aa91-92F-99 peptide, it is likely that the aa91-92F-99 peptide either is not created following endogenous processing of 92F mutantinfected cells or, if present, does not compete for binding to H2-K d within the lumen of the ER. Although tyrosine is the most frequently observed amino acid at the position 2 anchor residue, phenylalanine has been shown to be the anchor residue for at least one endogenously derived H2-K d binding peptide (11) . Such a discrepancy between the ability of a peptide to bind targets when added exogenously and the absence of apparent MHC class I loading following endogenous processing has also been seen in transient transfection systems in which octamer or nanomer peptides which could sensitize targets exogenously were not found at the cell surface following endogenous processing and proposed entry into the MHC class I presentation pathway (18) .
Antilisterial CTLs from mice immunized with the 92F mutant do not lyse targets pulsed with any of the LLO-derived determinants which satisfy the H2-K d motif and have been shown to bind H2-K d (28) . In the absence of CTL responses against the LLO aa91-99 determinant, antilisterial CTLs do not develop against any of the other H2-K d -binding LLO nanomer peptides. This suggests that for BALB/c mice immunized with wild-type L. monocytogenes, a hierarchy of LLO-derived peptides which can serve as MHC class I-presented targets does not account for the immunodominance of LLO aa91-99 as a CTL target. That is, in the absence of binding of the LLO aa91-99 epitope, any one of the other LLO determinants does not simply take its place (Fig. 6) . (In an MHC class II I-E k presentation model of the Staphylococcus aureus nuclease protein, presentation of subdominant domains was observed following anchor residue changes within the dominant 86-100 determinant [21] .) Given that LLO aa413-421 and LLO 479-487 appear to have affinities for H2-K d similar to that of LLO aa91-99 (28), it might be expected that if these nanomer peptides were available within the lumen of the ER, in the absence of LLO aa91-99 one or both of them would be transported with MHC class I to the cell surface and cause the induction of peptide-specific CTLs. However, 92F mutant-immune CTLs do not lyse LLO aa413-421-or aa479-487-sensitized targets, FIG. 7 . 92F mutant LLO is a target of H2 b -restricted antilisterial CTLs. C57BL/6 mice were immunized with 0.1 LD 50 of either wild-type L. monocytogenes (black bars) or the 92F mutant (gray bars), and 10 to 14 days later, immune spleen cells were stimulated in culture with an LLO ϩ B. subtilis construct for 72 h and used as antilisterial CTLs. C57BL/6-derived BM-MAC monolayers were infected with L. monocytogenes at an MOI of 10 to 20 and used as targets of antilisterial CTLs. The E/T ratio for the CFU reduction assay was 20:1. The CFU reduction assay was terminated 4 h following addition of antilisterial CTLs. The data are presented as percents CFU reduction, calculated as described in Materials and Methods, and are from one representative experiment of three performed. Lm, L. monocytogenes.
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